Drug Trial Radar · NCT05396391
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Jun 22, 2022
Primary completion
May 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- SUNHO(China)BioPharmaceutical CO., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.
Conditions
- Advanced Malignant Tumors
Interventions
IAP0971Drug
IAP0971 should be subcutaneous injected,q2w
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety of IAP0971 (Phase I)Time frame: Through finishing Phase I, an average of 1 year
- To evaluate the effectiveness of IAP0971 (Phase IIa)Time frame: Until disease progression, assessed up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.